Is Broach Lifecare overvalued or undervalued?

As of 11 August 2025, Broach Lifecare's valuation grade has moved from attractive to risky, indicating a shift in its perceived investment quality. The company is currently considered overvalued. Key ratios include a PE ratio of 13.05, an EV to EBITDA of 12.98, and a ROCE of 13.19%.
In comparison to its peers, Broach Lifecare's valuation metrics are significantly lower than those of Max Healthcare, which has a PE ratio of 108.47, and Apollo Hospitals, with a PE ratio of 71.93. This stark contrast suggests that while Broach Lifecare may appear overvalued relative to its own historical performance, it is still trading at a discount compared to some of the more expensive players in the healthcare sector. Notably, Broach Lifecare has outperformed the Sensex year-to-date, with a return of 5.93% compared to the Sensex's 3.15%.